

Technology/ Title	Cutting Alzheimer's Risk by 45%: Explore Our Innovative Pharmaceutical Combination Therapy	
Subtitle	Targeting Dysregulated Cellular Roles of Beta-Amyloid for Early Alzheimer's Management	
Technology Type	<input type="checkbox"/> Biotechnology	<input type="checkbox"/> Device/Diagnostics
	<input checked="" type="checkbox"/> Pharmaceutical	<input type="checkbox"/> Others: _____
Contact Person	Name: Stella Kao	Title: Manager
	Telephone(work): +886-37-206166 ext. 33208	Mobile:
	Email: stellakao@nhri.edu.tw	
Link	https://mg.nhri.edu.tw/investigators/dr-jyh-lyh-juang/	
Technology Description	<p>Our drug innovation stems from the identification of a novel cellular function of Aβ42 in metabolic modulation. Designed as a combination therapy, it aims to restore the disrupted metabolism characteristic of early Alzheimer's disease by targeting a newly discovered Aβ42 receptor responsible for this process. In preclinical studies, our drug effectively mitigated brain pathology in early AD mice. Remarkably, retrospective population-based analysis revealed a more than 55% reduction in the incidence of dementia associated with the use of this combination drug. These promising findings suggest that our combination drug has the potential to enter clinical trials directly for early intervention in AD. We are currently focused on developing a patch to deliver this combination drug directly to a specific tissue for therapy. This will not only lower the required doses needed to achieve therapeutic effects but also help differentiate the new therapy from the old drug used off-label, enhancing its market appeal and commercial success.</p>	

Intellectual Property	PCT, USA patent
Key Publications	unpublished
Business Opportunity	IP technology transfer and collaboration